TTR and rheumatoid arthritis: 2014) and juvenile idiopathic arthritis (Clement et al. 2016). Misfolding, aggregation, and oxidation of TTR enhanced its immunogenicity in a transgenic mouse model (Clement et al. 2016) and other posttranslational modifications of TTR were observed in human RA sera (Ni et al. 2013). However, there was no difference in autoantibodies against TTR between OA patients and healthy controls (Sharma et al. 2014).